ALLMedicine™ Alveolar Soft Part Sarcoma Center

Nov 26th, 2021 - Arm 2, the Axitinib Plus Pembrolizumab Expansion Cohort, did not open.

Nov 5th, 2021 - Brain metastasis is a rare condition among patients with soft tissue sarcoma (STS), and its precise incidence remains unclear. The aim of this study was to investigate which patients should be screened for brain metastasis. We identified all patie...

Oct 18th, 2021 - Alveolar soft part sarcoma (ASPS) has the highest incidence of brain metastasis amongst sarcomas. There is a paucity of literature published focusing on radiation therapy for this condition. This is a single centre retrospective review of the trea...

Aug 3rd, 2021 - Among all Soft Tissue sarcomas there are some subtypes with low incidence and/or peculiar clinical behaviour, that need to be consider separately. Most of them are orphan diseases, whose biological characteristics imply a clearly different diagnos...

Jul 22nd, 2021 - Alveolar Soft Part Sarcoma is one of the less commonly diagnosed soft tissue sarcoma subtypes, an infrequent subtype within the already rare category of human malignancy of sarcoma. In this article we will summarize the histopathological features,...

Nov 26th, 2021 - Arm 2, the Axitinib Plus Pembrolizumab Expansion Cohort, did not open.

Apr 27th, 2021 - Background: Alveolar soft part sarcoma (ASPS) is a rare, highly vascular tumor accounting for less than 1% of soft tissue sarcomas. There is no effective systemic treatment for patients with metastatic ASPS. Little is known with regards to relevan...

Feb 12th, 2021 - Background and introduction Metastasis is the main cause of death in cancer patients and often epithelial-to-mesenchymal transition (EMT) is advocated as the basic mechanism, although some limitations have been identified [1,2] Recently Fang and c...

Feb 8th, 2013 - This is a multi-center, single arm, two-stage phase 2 study of ARQ 197 in patients with microphthalmia transcription factor associated (MiT) tumors. ARQ 197 is a novel small molecule drug designed to block the activity of c-Met, which is thought t...

Oct 6th, 2021 - Jonathan C. Trent, MD, PhD, professor and associate director for Clinical Research at the Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses research efforts in bone and soft tissue sarcomas. Recently, several adv...

Jul 29th, 2021 - Chordoma is described as an extremely rare sarcoma that attacks the bones of the spine and base of the skull. It is the most common tumor of the sacrum and cervical spine, accounting for about 3% of all bone tumors and about 20% of primary spinal ...

Apr 28th, 2021 - Mark Socinski, MD: Dr Patel, you I think said early on that you had a handful of these patients with NTRK fusion-positive lung cancer. I wonder if you could tell us about your experience. Jyoti Patel, MD, FASCO: Primarily, I am prescribing more...

Dec 20th, 2020 - Breelyn Wilky, MD Excitement continues to surround the potential role of immunotherapy agents in the treatment of patients with sarcoma, according to Breelyn Wilky, MD. In November, The European Commission granted an accelerated approval to olar...

Dec 20th, 2020 - Data from the sarcoma cohort of the phase 2 AcSé basket study presented during the 2020 ESMO Virtual Congress showed that pembrolizumab (Keytruda) monotherapy prolonged progression-free survival (PFS) in selected rare sarcoma subtypes, supporting ...